Literature DB >> 23674846

Annexin A1: A new immunohistological marker of cholangiocarcinoma.

Nuttanan Hongsrichan1, Rucksak Rucksaken, Yaovalux Chamgramol, Porntip Pinlaor, Anchalee Techasen, Puangrat Yongvanit, Narong Khuntikeo, Chawalit Pairojkul, Somchai Pinlaor.   

Abstract

AIM: To evaluate a new immunohistological marker, annexin A1 (ANXA1), in cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC).
METHODS: Expression of ANXA1 protein was investigated in liver tissues from patients with CCA and HCC by immunohistochemistry. Its expression on differences stages of tumor development was investigated in hamster CCA tissues induced by Opisthorchis viverrini and N-nitrosodimethylamine. Moreover, mRNA expression of ANXA1 was assessed in CCA cell lines by quantitative real-time polymerase chain reaction and silencing of ANXA1 gene expression using small interfering RNA.
RESULTS: In human CCA tissue arrays, immunohistochemical analysis revealed that the positive expression of ANXA1 was 94.1% (64/68 cases) consisting of a high expression (66.2%, 45/68 cases) and a low expression (33.8%, 23/68 cases). However, expression of ANXA1 protein was negative in all histologic patterns for HCC (46/46 cases) and healthy individuals (6/6 cases). In hamster with opisthorchiasis-associated CCA, the expression of ANXA1 was observed in the cytoplasm of inflammatory cells, bile duct epithelia and tumor cells. Grading scores of ANXA1 expression were significantly increased with tumor progression. In addition, mRNA expression of ANXA1 significantly increased in all of the various CCA cell lines tested compared to an immortalized human cholangiocyte cell line (MMNK1). Suppressing the ANXA1 gene significantly reduced the matrix metalloproteinase (MMP) 2 and MMP9, and transforming growth factor-β genes, but increased nuclear factor-κB gene expression.
CONCLUSION: ANXA1 is highly expressed in CCA, but low in HCC, suggesting it may serve as a new immunohistochemical marker of CCA. ANXA1 may play a role in opisthorchiasis-associated cholangiocarcinogenesis.

Entities:  

Keywords:  Annexin A1; Biomarker; Cholangiocarcinoma; Hepatocellular carcinoma; Opisthorchis viverrini

Mesh:

Substances:

Year:  2013        PMID: 23674846      PMCID: PMC3646135          DOI: 10.3748/wjg.v19.i16.2456

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  36 in total

1.  The role of annexin A1 in expression of matrix metalloproteinase-9 and invasion of breast cancer cells.

Authors:  Hyereen Kang; Jesang Ko; Sung-Wuk Jang
Journal:  Biochem Biophys Res Commun       Date:  2012-05-26       Impact factor: 3.575

2.  Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis.

Authors:  A Rullier; B Le Bail; R Fawaz; J F Blanc; J Saric; P Bioulac-Sage
Journal:  Am J Surg Pathol       Date:  2000-06       Impact factor: 6.394

3.  Annexin I regulates SKCO-15 cell invasion by signaling through formyl peptide receptors.

Authors:  Brian A Babbin; Winston Y Lee; Charles A Parkos; L Matthew Winfree; Adil Akyildiz; Mauro Perretti; Asma Nusrat
Journal:  J Biol Chem       Date:  2006-05-04       Impact factor: 5.157

Review 4.  Epidemiology of cholangiocarcinoma: an update focusing on risk factors.

Authors:  Hai-Rim Shin; Jin-Kyoung Oh; Eric Masuyer; Maria-Paula Curado; Veronique Bouvard; Yue-Yi Fang; Surapon Wiangnon; Banchob Sripa; Sung-Tae Hong
Journal:  Cancer Sci       Date:  2009-12-04       Impact factor: 6.716

Review 5.  Cholangiocarcinoma: lessons from Thailand.

Authors:  Banchob Sripa; Chawalit Pairojkul
Journal:  Curr Opin Gastroenterol       Date:  2008-05       Impact factor: 3.287

Review 6.  Annexin A1 and glucocorticoids as effectors of the resolution of inflammation.

Authors:  Mauro Perretti; Fulvio D'Acquisto
Journal:  Nat Rev Immunol       Date:  2009-01       Impact factor: 53.106

Review 7.  Current surgical treatment for bile duct cancer.

Authors:  Yasuji Seyama; Masatoshi Makuuchi
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

8.  [Expression of annexin I in different histological types of carcinomas].

Authors:  Li-Yan Xue; Liang-Hong Teng; Shuang-Mei Zou; Li-Qun Ren; Shan Zheng; Wei Luo; Rui Bi; Ning Lü
Journal:  Zhonghua Zhong Liu Za Zhi       Date:  2007-06

Review 9.  Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms.

Authors:  Sanjay Kakar; Allen M Gown; Zachary D Goodman; Linda D Ferrell
Journal:  Arch Pathol Lab Med       Date:  2007-11       Impact factor: 5.534

10.  Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?

Authors:  Shahid A Khan; Shireen Emadossadaty; Nimzing G Ladep; Howard C Thomas; Paul Elliott; Simon D Taylor-Robinson; Mireille B Toledano
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

View more
  17 in total

1.  Cytokine/chemokine secretion and proteomic identification of upregulated annexin A1 from peripheral blood mononuclear cells cocultured with the liver fluke Opisthorchis viverrini.

Authors:  Nuttanan Hongsrichan; Kitti Intuyod; Porntip Pinlaor; Jarinya Khoontawad; Puangrat Yongvanit; Chaisiri Wongkham; Sittiruk Roytrakul; Somchai Pinlaor
Journal:  Infect Immun       Date:  2014-03-10       Impact factor: 3.441

2.  Correlation of ANXA1 expression with drug resistance and relapse in bladder cancer.

Authors:  Shuliang Yu; Qian Meng; Huihui Hu; Man Zhang
Journal:  Int J Clin Exp Pathol       Date:  2014-08-15

3.  Increased expression of annexin A1 predicts poor prognosis in human hepatocellular carcinoma and enhances cell malignant phenotype.

Authors:  Ya Lin; Guoqing Lin; Wenzheng Fang; Hongwei Zhu; Kedan Chu
Journal:  Med Oncol       Date:  2014-11-21       Impact factor: 3.064

4.  MicroRNA-26a regulates ANXA1, rather than DAL-1, in the development of lung cancer.

Authors:  Tonghui Cai; Xiaoying Guan; Hongyan Wang; Ying Fang; Jie Long; Xiaobin Xie; Yajie Zhang
Journal:  Oncol Lett       Date:  2018-02-14       Impact factor: 2.967

5.  Immunohistochemical Markers Distinguishing Cholangiocellular Carcinoma (CCC) from Pancreatic Ductal Adenocarcinoma (PDAC) Discovered by Proteomic Analysis of Microdissected Cells.

Authors:  Juliet Padden; Maike Ahrens; Julia Kälsch; Stefanie Bertram; Dominik A Megger; Thilo Bracht; Martin Eisenacher; Peri Kocabayoglu; Helmut E Meyer; Bence Sipos; Hideo A Baba; Barbara Sitek
Journal:  Mol Cell Proteomics       Date:  2015-12-07       Impact factor: 5.911

6.  Identification of functional modules by integration of multiple data sources using a Bayesian network classifier.

Authors:  Jinlian Wang; Yiming Zuo; Lun Liu; Yangao Man; Mahlet G Tadesse; Habtom W Ressom
Journal:  Circ Cardiovasc Genet       Date:  2014-04

7.  Annexin A1 Is a Potential Prognostic Marker for, and Enhances the Metastasis of, Cholangiocarcinoma.

Authors:  Kwuntida U Kotepui; Sumalee Obchoei; Kulthida Vaeteewoottacharn; Seiji Okada; Sopit Wongkham; Kanlayanee Sawanyawisuth
Journal:  Asian Pac J Cancer Prev       Date:  2022-02-01

8.  Expression and diagnostic values of calretinin and CK5/6 in cholangiocarcinoma.

Authors:  Lanjing Zhang; Renee Frank; Emma E Furth; Amy F Ziober; Virginia A LiVolsi; Paul J Zhang
Journal:  Exp Hematol Oncol       Date:  2014-04-23

9.  Annexin-A1 regulates microRNA-26b* and microRNA-562 to directly target NF-κB and angiogenesis in breast cancer cells.

Authors:  Durkeshwari Anbalagan; Gracemary Yap; Yi Yuan; Vijay K Pandey; Wai Hoe Lau; Suruchi Arora; Pradeep Bist; Justin S B Wong; Gautam Sethi; Peter M Nissom; Peter E Lobie; Lina H K Lim
Journal:  PLoS One       Date:  2014-12-23       Impact factor: 3.240

10.  Xuebijing Protects Rats from Sepsis Challenged with Acinetobacter baumannii by Promoting Annexin A1 Expression and Inhibiting Proinflammatory Cytokines Secretion.

Authors:  Xian-Di He; Yan Wang; Qiong Wu; Hua-Xue Wang; Zhen-Dong Chen; Rong-Sheng Zheng; Zi-Shu Wang; Jun-Bin Wang; Yan Yang
Journal:  Evid Based Complement Alternat Med       Date:  2013-11-28       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.